Objective: To understand the current status of screening, diagnosis, and treatment and analyze the factors influencing micro-elimination strategy, so as to achieve hepatitis C elimination in hospital. Methods: Anti-HCV and HCV RNA test results of patients from October 2017 to September 2020 were retrospectively analyzed. Anti-HCV positive rates and factors influencing different genders, ages, places of residence and departments were analyzed. After comparing anti-HCV-positive patients with HCV RNA-positive patients with duplicate entries in "Name" and "Date of birth", the data were divided into three categories: anti-HCV positive without HCV RNA test, HCV RNA positive in single test, and HCV RNA positive many times in multiple tests. The above three types of patients were followed-up by telephone. According to the hospital follow-up results, current status of diagnosis and treatment and the factors influencing the micro-elimination strategy of hepatitis C were studied and analyzed. The comparison of data between groups were performed using χ(2) or χ(2) continuity-correction test. Results: Anti-HCV positive detection rate was 1.34% (899/66 866). The positive rate of male patients aged 40 and over residing in cities was significantly higher than female patients under 40 years old residing in rural areas, and the difference was statistically significant (χ(2) = 55.178, 264.11, 36, 351, P < 0.05). There were 90 (10.02%) and 809 cases (89.98%) in outpatient and inpatient departments, respectively, with no statistically significant difference between the two (χ(2) = 0.002, P > 0.05). The total number of anti-HCV positive cases were 196 in Gastroenterology (22.0%), 75 in Respiratory and Critical Care Medicine (8.3%), 74 in Neurology (8.2%), 63 in Orthopedics (7.0%) and 55 in Endocrinology departments (6.1%), and the difference in the positive rate among different departments were also statistically significant (χ(2) = 271.585, P < 0.05). Among the 480 cases who were followed-up, 215 (44.79%) were lost to follow-up, 84 cases (39.07%) were unregistered, 77 cases (16.04%) were untreated, 15 cases (19.48%) were unaware of their state of illness, 46 cases (59.74%) were diagnosed without concern, 16 cases (20.78%) were diagnosed but did not take medicine, 60 cases were under treatment, and 29 cases were mostly on counterfeit drugs (48.33%). Conclusion: Comprehensive diagnosis and treatment education to non-specialist clinicians and timely manner regular follow-up of patients is a key factor and an important link to formulate a simple, easy and sustainable model to improve the efficiency of screening, diagnosis, and treatment of hepatitis C micro-elimination strategy in hospital. In addition, it will also play an important role in achieving the strategic goal of "eliminating hepatitis C as a public health threat by 2030".
目的： 了解医院内丙型肝炎筛查及诊治现状，分析医院内丙型肝炎微消除策略影响因素，以期达到院内丙型肝炎消除。 方法： 回顾性分析2017年10月至2020年9月患者抗-HCV、HCV RNA检测结果，分析不同性别、年龄、居住地以及不同科室抗-HCV阳性率及其影响因素。将抗-HCV阳性患者与HCV RNA阳性患者以"姓名"和"出生日期"进行重复项比对后，将数据分为三类：即抗-HCV阳性未行HCV RNA检测者、HCV RNA单次检测阳性者、HCV RNA多次检测仍阳性者。对以上三类患者行电话随访，根据随访结果，分析院内丙型肝炎诊治现状，研究医院内丙型肝炎微消除策略影响因素。组间比较采用χ(2)检验或连续性校正的χ(2)检验。 结果： 抗-HCV阳性检测率1.34%（899/66 866），其中男性、40岁及以上、居住于城市的患者阳性率明显高于女性、40岁以下及居住于农村的患者，差异均有统计学意义（χ(2)值分别为55.178、264.11、36、351，P < 0.05）；病例来源于门诊90例（10.02%），住院部809例（89.98%），两者差异无统计学意义（χ(2) = 0.002，P > 0.05）。抗-HCV阳性患者总数量分别为消化内科196例（22.0%），呼吸与危重症医学科75例（8.3%），神经内科74例（8.2%），骨科63例（7.0%），内分泌科55例（6.1%），不同科室间其阳性率差异亦有统计学意义（χ(2) = 271.585，P < 0.05）。随访480例患者中，失访者215例（44.79%），其中电话为空号者84例（39.07%）；未治疗者77例（16.04%），其中不知晓病情者15例（19.48%）；已诊断未重视患者46例（59.74%），已诊断未服药患者16例（20.78%）；服用直接抗病毒药物治疗患者60例，其中服用同类药物29例（48.33%）。 结论： 深入非专科进行丙型肝炎诊治宣教与及时常态化随访患者，是医院内丙型肝炎微消除策略关键因素，是制定简便、易行、可持续模式的重要环节，以此提升院内丙型肝炎筛查率、诊断率、治疗率，在实现"2030消除丙型肝炎公共卫生危害"的战略目标中发挥重要作用。.
Keywords: Elimination in hospital; Hepatitis C; Screening strategy; Status survey.